Chronic Hepatitis C
Conditions
Keywords
Hepatitis, Hepatitis C
Brief summary
The purpose of this study is to compare several Debio 025 (alisporivir)/peg-IFNα2a/ribavirin triple therapies with the current standard of care (SOC) in treatment naïve chronic hepatitis C genotype 1 patients.
Detailed description
This is an international, multicentre, randomised, double-blind, placebo-controlled, 4-arm, parallel-group, multiple dose phase II study comparing 3 Debio 025 (alisporivir)/peg-IFNα2a/ribavirin regimens to SOC treatment in treatment naïve chronic HCV genotype 1 patients. Patients are randomised into 1 of 4 arms receiving either Debio 025/peg-IFNα2a/ribavirin triple therapy for a fixed treatment duration of 48 weeks (Treatment A) or 24 weeks (Treatment B), Debio 025/peg-IFNα2a/ribavirin triple therapy for a response-based treatment duration of 24 or 48 weeks (Treatment C), or blinded SOC treatment for 48 weeks (Treatment D). Follow-up is 24 weeks in all treatment arms.
Interventions
DRUGDebio 025
Debio 025 supplied in soft gel capsules
DRUGPeg-IFNα2a
Peg-IFNα2a supplied in pre-filled syringes
DRUGRibavirin
Ribavirin supplied in tablets
DRUGDebio 025 placebo
Debio 025 placebo supplied in soft gel capsules
Sponsors
Parexel
Debiopharm International SA
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Males or females aged ≥ 18 and ≤ 65 years. * Body mass index (BMI) ≥ 18 and ≤ 32 kg/m\^2. * Hepatitis B surface antigen (HbsAg) negative and HIV-1 negative. * Serological diagnosis of chronic hepatitis C viral infection genotype 1 for \> 6 months. * Chronic liver disease consistent with chronic hepatitis C infection on a biopsy or FibroScan® obtained within the past 24 months (36 months for patients with incomplete/transition to cirrhosis). * Previously untreated for hepatitis C virus (HCV) infection (approved or investigational drug). * Plasma HCV RNA level lower limit ≥ 100 IU/ml assessed by quantitative polymerase chain reaction (qPCR) or equivalent; no upper limit. * Neutrophil count ≥ 1500/µL; hemoglobin (Hb) ≥ 12g/dL for females and ≥ 13g/dL for males; platelets ≥ 90,000/µL. * Patients with incomplete/transition to cirrhosis on biopsy or an elasticity score between 9.5 and 14 kPa on FibroScan must have an abdominal ultrasound (US), computed tomographic (CT) scan, or magnetic resonance imaging (MRI) scan without evidence of hepatocellular carcinoma (within 2 months prior to randomisation) and a serum alpha-foetoprotein (AFP) \< 100 ng/mL. * Aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) \< 5 times the upper limit of normal. * Normal or compensated liver function and absence of complicated portal hypertension as documented by the following: * No history of bleeding oesophageal varices; * Absence of ascites; * Absence of encephalopathy; * Albumin ≥ 35 g/L; * Total bilirubin ≤ 1.8 mg/dL (≤ 30 µmol/L); * Prothrombin (INR ≤ 1.5). * Creatinine clearance \> 50 mL/min. * Thyroid stimulating hormone (TSH) within normal range; * All patients should be informed about Debio 025 and ribavirin foetotoxicity: * Females may participate if they are surgically sterile or post-menopausal. Pre-menopausal females may participate if they use 2 reliable contraceptive methods (oral contraceptive + barrier method). The contraceptive regimen must be maintained during the treatment period and for 4 months after the last Debio 025 or ribavirin dose. * Male patients must be surgically sterile or use 2 reliable contraceptive methods (oral contraceptive + barrier method). The contraceptive regimen must be maintained during the treatment period and for 7 months after the last Debio 025 or ribavirin dose. * Signed informed consent before any study procedures. * Negative pregnancy test within one week of first investigational product administration for female patients of child bearing potential.
Exclusion criteria
* Treatment with any investigational drug within 6 months prior to the first dose of investigational product. * HCV genotype different from genotype 1. * Any previous HCV treatment (approved or investigational). * Histologic evidence of complete hepatic cirrhosis (including compensated cirrhosis) based on a previous liver biopsy (if available). * Ongoing or recent use of any other medication (including over the counter medication and herbal products) within 2 weeks before study start or within 5 drug half-lives of that medication (whichever is longer) that are known inhibitors/inducers of cytochrome P450 (CYP450) 3A, substrates of P-glycoprotein 1 (P-gP), or substrates/inhibitors of organic anion-transporting polypeptides (OATP), multidrug resistance-associated protein 2 (MRP2), or bile salt export pump (BSEP) and are mentioned in the list of unauthorised medications; * Any medical contraindications to peg-IFNα2a and/or ribavirin treatment; * Any other cause of relevant liver disease other than HCV including but not limited to hepatitis B virus (HBV), drug- or alcohol-related cirrhosis, autoimmune hepatitis, haemochromatosis, Wilson's disease, nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), or primary biliary cirrhosis (PBC). * Any other condition which, in the opinion of the Investigator, would make the patient unsuitable for enrollment or could interfere with the patient participating in and completing the study. Patients with risk factors (hypertension or diabetes) need to have an ophthalmologic investigation (including fundoscopy). * History of moderate, severe, or uncontrolled psychiatric disease, especially depression, including a history of hospitalisation or prior suicidal attempt. * Uncontrolled arterial hypertension, ie, patients with systolic BP ≥ 160 mmHg and/or diastolic BP ≥ 100 mmHg. * History of pancreatitis, uncontrolled diabetes mellitus, or retinopathy. * Anti-nuclear antibody (ANA) titre \> 1:640 at screening and/or evidence of autoimmune hepatitis on liver biopsy. * Alcohol consumption \> 20 g/day for females and \> 30 g/day for males. * History of major organ transplantation with an existing functional graft. * Pregnancy or lactation. * Haemoglobinopathies (thalassaemia major, sickle cell anaemia or drepanocytosis). * Familial history of severe neonatal cholestasis or pregnancy cholestasis. * Evidence of an active or suspected cancer, or a history of malignancy where the risk of recurrence is ≥ 20% within 2 years.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of participants achieving sustained viral response (SVR) 72 weeks after treatment start | 72 weeks after treatment start | SVR is defined as hepatitis C virus (HCV) RNA \< 10 IU/mL (undetectable). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of participants achieving a complete early viral response (cEVR) after 12 weeks of treatment | 12 weeks after treatment start | cEVR is defined as HCV RNA level \< 10 IU/mL after 12 weeks of treatment. |
| Percentage of participants achieving an early viral response (EVR) after 12 weeks of treatment | 12 weeks after treatment start | EVR is defined as a decrease from baseline of the HCV RNA level by \> 2 log10 or undetectable (\< 10 UI/mL) after 12 weeks of treatment. |
| Percentage of participants achieving a rapid viral response (RVR) after 4 weeks of treatment | 4 weeks after treatment start | RVR is defined as HCV RNA level \< 10 IU/mL after 4 weeks of treatment. |
| Percentage of participants achieving a sustained viral response 12 weeks after the end of treatment (SVR 12) | 12 weeks after end of treatment (Week 40 or Week 64) | SVR 12 is defined as HCV RNA level \< 10 IU/mL 12 weeks after the end of treatment (Week 40 or Week 64). |
| Percentage of participants with sustained viral response 24 weeks after the end of treatment (SVR 24) | 24 weeks after end of treatment (Week 52 or Week 76 | SVR 24 is defined as HCV RNA level \< 10 IU/mL 24 weeks after the end of treatment (Week 52 or Week 76). |
| Percentage of participants achieving an end-of-treatment response (ETR) at treatment end | at end of treatment (Week 28 or Week 52) | ETR is defined as HCV RNA level \< 10 IU/mL at the end of treatment (Week 24 or Week 48). |
Countries
Belgium, France, Germany, Italy, Poland, Romania, Spain
Outcome results
None listed